Citation
Sivera, Piera, et al. "Use of the Novel Thrombopoietin Receptor-agonist Romiplostim, in Combination With Steroids and Immunoglobulins for the Increase of Platelets Prior to Splenectomy, in Refractory Immune Thrombocytopenia: a Case Report." Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis, vol. 23, no. 4, 2012, pp. 331-4.
Sivera P, Ruella M, Gueli A, et al. Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report. Blood Coagul Fibrinolysis. 2012;23(4):331-4.
Sivera, P., Ruella, M., Gueli, A., Hu, H., Wade, M., & Tarella, C. (2012). Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report. Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis, 23(4), 331-4. https://doi.org/10.1097/MBC.0b013e3283513a97
Sivera P, et al. Use of the Novel Thrombopoietin Receptor-agonist Romiplostim, in Combination With Steroids and Immunoglobulins for the Increase of Platelets Prior to Splenectomy, in Refractory Immune Thrombocytopenia: a Case Report. Blood Coagul Fibrinolysis. 2012;23(4):331-4. PubMed PMID: 22343685.
TY - JOUR
T1 - Use of the novel thrombopoietin receptor-agonist romiplostim, in combination with steroids and immunoglobulins for the increase of platelets prior to splenectomy, in refractory immune thrombocytopenia: a case report.
AU - Sivera,Piera,
AU - Ruella,Marco,
AU - Gueli,Angela,
AU - Hu,Huijing,
AU - Wade,Muhamed,
AU - Tarella,Corrado,
PY - 2012/2/21/entrez
PY - 2012/2/22/pubmed
PY - 2012/8/28/medline
SP - 331
EP - 4
JF - Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
JO - Blood Coagul Fibrinolysis
VL - 23
IS - 4
N2 - This case report describes a patient with relapsed primary immune thrombocytopenic purpura (ITP), in which splenectomy was not possible due to the persistence of a low platelet count despite treatment with corticosteroids, intravenous immunoglobulins (IVIG) and platelet transfusion treatment. As an attempt to increase platelet count prior to performing splenectomy, the thrombopoietin receptor agonist, romiplostim, was administered in combination with steroids and IVIG. A single administration of romiplostim was found to be markedly effective, allowing a rapid and notable platelet increase, required for a well tolerated splenectomy. This case confirms the potent activity of romiplostim in ITP, and indicates that patients with recurrent primary ITP who are unresponsive to conventional immunosuppressive therapy may benefit from the addition of a short course of romiplostim.
SN - 1473-5733
UR - https://www.unboundmedicine.com/medline/citation/22343685/Use_of_the_novel_thrombopoietin_receptor_agonist_romiplostim_in_combination_with_steroids_and_immunoglobulins_for_the_increase_of_platelets_prior_to_splenectomy_in_refractory_immune_thrombocytopenia:_a_case_report_
L2 - https://doi.org/10.1097/MBC.0b013e3283513a97
DB - PRIME
DP - Unbound Medicine
ER -